<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6713">
  <stage>Registered</stage>
  <submitdate>8/09/2017</submitdate>
  <approvaldate>8/09/2017</approvaldate>
  <nctid>NCT03287245</nctid>
  <trial_identification>
    <studytitle>A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera</studytitle>
    <scientifictitle>A Phase II, Single-Arm, Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Patients With Hydroxyurea-Resistant/Intolerant Polycythemia Vera</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2017-000861-58</secondaryid>
    <secondaryid>NP39761</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Polycythemia Vera</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Idasanutlin

Experimental: Idasanutlin - 150 milligrams (mg), once daily for 5 days, every 28 days, until treatment discontinuation or up to 2 years.


Treatment: drugs: Idasanutlin
150 milligrams (mg) orally, once daily for 5 days, every 28 days, until treatment discontinuation or up to 2 years.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Composite Response at Week 32 for Participants With Splenomegaly at Baseline - Composite response is defined as hematocrit (Hct) control without phlebotomy and &gt; 35% decrease in spleen size by imaging at Week 32. Hct control is defined as protocol-specified ineligibility for phlebotomy between Weeks 8 to 32 and = 1 instance of phlebotomy eligibility between first dose and Week 8. Eligibility for phlebotomy is defined as a Hct of = 45% that was = 3% higher than baseline level or a Hct of &gt; 48% at Week 32.</outcome>
      <timepoint>Week 32</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Hematocrit (Hct) Control Without Phlebotomy at Week 32 for Participants Without Splenomegaly at Baseline - Hct control is defined as protocol-specified ineligibility for phlebotomy between Weeks 8 to 32 and = 1 instance of phlebotomy eligibility between first dose and Week 8. Eligibility for phlebotomy is defined as a Hct level = 45% that was = 3% higher than baseline level or a Hct level of &gt; 48% at Week 32.</outcome>
      <timepoint>Week 32</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Response per Modified European Leukemia Net (ELN) Criteria at Week 32 for Ruxolitinib-Naïve Participants and All Participants Irrespective of Prior Ruxolitinib Exposure - Complete hematologic response (CHR) includes all of the following: Hct &lt; 45% without phlebotomy; platelet count = 400 × 10^9/liter (L); white blood cell count = 10 × 10^9/L; normal spleen size on imaging; and no disease-related symptoms. Partial hematologic response (PHR): in participants who do not fulfill the criteria for complete response: Hct &lt; 45% without phlebotomy or response in 3 or more of the other criteria. No response (NR): any response that does not satisfy partial response. Progressive disease (PD): increased bone marrow fibrosis from baseline, and/or transformation to myelofibrosis (MF), myelodysplastic syndrome (MDS) or acute leukemia.</outcome>
      <timepoint>Week 32</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Response, Including Percentage of Participants With Durable Response Lasting at Least 12 Weeks - Complete hematologic response (CHR) includes all of the following: Hct &lt; 45% without phlebotomy; platelet count = 400 × 10^9/liter (L); white blood cell count = 10 × 10^9/L; normal spleen size on imaging; and no disease-related symptoms. Partial hematologic response (PHR): in participants who do not fulfill the criteria for complete response: Hct &lt; 45% without phlebotomy or response in 3 or more of the other criteria. No response (NR): any response that does not satisfy partial response. Progressive disease (PD): increased bone marrow fibrosis from baseline, and/or transformation to myelofibrosis (MF), myelodysplastic syndrome (MDS) or acute leukemia.</outcome>
      <timepoint>Week 32</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Composite Response at Week 32 for Participants With Splenomegaly at Baseline Irrespective of Prior Ruxolitinib Exposure - Composite response is defined as hematocrit (Hct) control without phlebotomy and &gt; 35% decrease in spleen size by imaging at Week 32. Hct control is defined as protocol-specified ineligibility for phlebotomy between Weeks 8 to 32 and = 1 instance of phlebotomy eligibility between first dose and Week 8. Eligibility for phlebotomy is defined as a Hct of = 45% that was = 3% higher than baseline level or a Hct of &gt; 48% at Week 32.</outcome>
      <timepoint>Week 32</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hematocrit (Hct) Control in Participants Without Splenomegaly at Baseline Irrespective of Prior Ruxolitinib Exposure - Hct control is defined as protocol-specified ineligibility for phlebotomy between Weeks 8 to 32 and = 1 instance of phlebotomy eligibility between first dose and Week 8. Eligibility for phlebotomy is defined as a Hct level = 45% that was = 3% higher than baseline level or a Hct level of &gt; 48% at Week 32.</outcome>
      <timepoint>Week 32</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With Abnormal Clinical Laboratory Findings</outcome>
      <timepoint>Up to 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) - An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not considered related to the study drug. A SAE is any experience that: results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is medically significant.</outcome>
      <timepoint>Up to 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Eastern Cooperative Oncology Group (ECOG) Performance Status - The ECOG performance status is a scale used to quantify cancer patients' general well-being and activities of daily life. The scale ranges from 0 to 5, with 0 denoting perfect health and 5 indicating death. The 6 categories are 0=Asymptomatic (Fully active, able to carry on all pre-disease activities without restriction), 1=Symptomatic but completely ambulatory (Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature), 2=Symptomatic, &lt; 50% in bed during the day (Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours), 3=Symptomatic, &gt; 50% in bed, but not bedbound (Capable of only limited self-care, confined to bed or chair 50% or more of waking hours), 4=Bedbound (Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair), 5=Death.</outcome>
      <timepoint>Up to 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With Abnormal Electrocardiogram (ECG) Findings, Vital Signs, and Physical Findings</outcome>
      <timepoint>Up to 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With Concomitant Medications</outcome>
      <timepoint>Up to 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum Serum Concentration Observed (Cmax) - Cmax is the maximum observed concentration of drug in blood plasma.</outcome>
      <timepoint>Day 1, Day 2, Day 5 of Cycle 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Trough Concentration (Ctrough) - Ctrough is the measured concentration of a drug at the end of a dosing interval at steady state.</outcome>
      <timepoint>Day 1, Day 2, Day 5 of Cycle 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time of Maximum Concentration Observed (tmax) - Tmax is the time elapsed from the time of drug administration to maximum plasma concentration.</outcome>
      <timepoint>Day 1, Day 2, Day 5 of Cycle 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clearance (CL) - CL is a measure of the body's elimination of a drug from plasma over time.</outcome>
      <timepoint>Day 1, Day 2, Day 5 of Cycle 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Apparent clearance (CL/F) - CL/F is a measure of the body's elimination of a drug from plasma over time, after oral administration.</outcome>
      <timepoint>Day 1, Day 2, Day 5 of Cycle 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Volume or Apparent Volume of Distribution (Vdss/F) - Vdss/F is the theoretical volume that would be necessary to contain the total amount of an administered drug at the same concentration that it is observed in the plasma.</outcome>
      <timepoint>Day 1, Day 2, Day 5 of Cycle 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the curve (AUC) - AUC (from zero to infinity) represents the total drug exposure over time.</outcome>
      <timepoint>Day 1, Day 2, Day 5 of Cycle 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Half-life (t1/2) - t1/2 is defined as the time required for the drug plasma concentration to be reduced to half.</outcome>
      <timepoint>Day 1, Day 2, Day 5 of Cycle 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Baseline and Mean Change from Baseline Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) - The MPN-SAF TSS is an assessment form to measure the severity of 9 clinically important symptoms of polycythemia vera. These include: early satiety, abdominal discomfort, inactivity, concentration issues, night sweats, itching, bone pain, fever, and weight loss. The participant provides a severity score for each additional symptom on a scale of 0 (none/absent) to 10 (worst imaginable). A tenth symptom, fatigue, is assessed using the "worst" fatigue item from the Brief Fatigue Inventory (BFI).</outcome>
      <timepoint>Day 1 of Cycle 1, Cycle 2, Cycle 3, Day 28 of Cycle 5, Week 32, every 3 cycles beyond Week 32, end of study (2 years) or 28 days post last dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Baseline and Mean Change from Baseline European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) - EORTC QLQ-C30: includes functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions use a 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale [1 'very poor' to 7 'Excellent']). Scores are averaged and transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.</outcome>
      <timepoint>Day 1 of Cycle 1, Cycle 2, Cycle 3, Day 28 of Cycle 5, Week 32, every 3 cycles beyond Week 32, end of study (2 years) or 28 days post last dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Baseline and Mean Change from Baseline Patient Global Impression of Change (PGIC) - The PGIC is a one-item measure used to assess perceived treatment benefit. Participants will be asked "Since the start of the treatment you've received in this study, your polycythemia vera (PV) symptoms are: 'very much improved', 'much improved', 'minimally improved', 'no change', 'minimally worse', 'much worse', and 'very much worse'.</outcome>
      <timepoint>Day 1 of Cycle 2, Cycle 3, Day 28 of Cycle 5, Week 32, every 3 cycles beyond Week 32, end of study (2 years) or 28 days post last dose</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Adults &gt; 18 years of age

          -  Documentation that the participant has met the revised 2016 World Health Organization
             (WHO) criteria for the diagnosis of polycythemia vera (PV)

          -  Hematocrit at initiation of idasanutlin &gt; 40%

          -  Phlebotomy-dependent participants with splenomegaly by magnetic resonance imaging
             (MRI) or computerized tomography (CT) imaging (= 450 cubic centimeters [cm^3]) or
             without splenomegaly (&lt; 450 cm^3, unpalpable, or prior splenectomy)

          -  Resistance to/intolerance to hydroxyurea according to modified European Leukemia Net
             (ELN) criteria

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

          -  Participants must be willing to submit the blood sampling and bone marrow sampling for
             the pharmacokinetic (PK) and pharmacodynamic analyses and exploratory biomarkers

          -  Adequate hepatic and renal function

          -  For women of childbearing potential: agreement to remain abstinent (refrain from
             heterosexual intercourse) or use non-hormonal contraceptive methods that result in a
             failure rate of &lt; 1% per year during the treatment period and for at least 14 days
             after the last dose of idasanutlin

          -  For men: Agreement to remain abstinent (refrain from heterosexual intercourse) or use
             contraceptive measures, and agreement to refrain from donating sperm during the
             treatment period and for at least 90 days after the last dose of idasanutlin to avoid
             exposing the embryo</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Meets the criteria for post-PV myelofibrosis as defined by the International Working
             Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)

          -  Blast phase disease (&gt;20% blasts in the marrow or peripheral blood)

          -  Clinically-significant thrombosis within 3 months of screening

          -  Participants who must receive CYP2C8 inhibitors, substrates and inducers, strong
             CYP3A4 inducers, or OATP1B1/3 substrates while on study. These must be discontinued 7
             days (inhibitors and substrates) or 14 days (inducers) prior to start of study
             medication

          -  Participants previously treated with murine double minute 2 (MDM2) antagonist
             therapies or participants receiving interferon-alpha, anagrelide, or ruxolitinib
             within 28 days or 5 half-lives, or hydroxyurea within 1 day, or participants receiving
             any other cytoreductive or investigational agents within 28 days or 5 half-lives of
             initial dose. Aspirin is permitted per treatment guidelines for PV unless medically
             contraindicated

          -  Participants with evidence of electrolyte imbalance such as hypokalemia, hyperkalemia,
             hypocalcemia, hypercalcemia, hypomagnesemia, and hypermagnesemia of Grade &gt; 1
             intensity, as per the National Cancer Institute Common Terminology Criteria for
             Adverse Events (NCI CTCAE), version 4.0, prior to dosing on Cycle 1 Day 1. Treatment
             for correction of electrolyte imbalances is permitted to meet eligibility

          -  Neutrophil count &lt; 1.5 × 10^9/liter (L) prior to dosing on Cycle 1 Day 1

          -  Platelet count = 150 × 10^9/L prior to dosing on Cycle 1 Day 1

          -  Women who are pregnant or breastfeeding

          -  Ongoing serious non-healing wound, ulcer, or bone fracture

          -  History of major organ transplant

          -  Uncontrolled intercurrent illness including, but not limited to hepatitis, concurrent
             malignancy, hepatitis A, B, and C, human immunodeficiency virus (HIV)-positive,
             ongoing or active infection, clinically significant cardiac disease (New York Heart
             Association Class III or IV), symptomatic congestive heart failure, unstable angina
             pectoris, ventricular arrhythmia, or psychiatric illness/social situations that would
             limit compliance with study requirements

          -  Participants with active gastrointestinal conditions (Crohn's disease, ulcerative
             colitis, diverticulosis associated colitis, and Behçet's disease)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>16/11/2017</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>15/07/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Peter MacCallum Cancer Centre; Department of Haematology - Melbourne</hospital>
    <postcode>3002 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lombardia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Toscana</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is an open-label, single-arm, study of idasanutlin monotherapy in participants with
      hydroxyurea (HU)-resistant/intolerant Polycythemia vera (PV).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03287245</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Reference Study ID: NP39761 www.roche.com/about_roche/roche_worldwide.htm</name>
      <address />
      <phone>888-662-6728 (U.S. only)</phone>
      <fax />
      <email>global-roche-genentech-trials@gene.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>